TARS Tarsus Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%
Returns
ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x
Cash quality & payout
Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $194.57M | $173.91M | $162.05M | $151.67M | $118.70M | $102.66M | $78.33M | $66.41M |
| Cost of revenue | $13.89M | $12.11M | $9.40M | — | $8.31M | $6.24M | $5.21M | — |
| Gross profit | $180.68M | $161.80M | $152.66M | — | $110.39M | $96.42M | $73.12M | — |
| R&D expense | $44.19M | $31.01M | $22.35M | $18.04M | $16.28M | $15.59M | $14.41M | $16.87M |
| SG&A expense | $168.02M | $150.70M | $136.43M | $130.68M | $108.63M | $103.01M | $85.00M | $69.03M |
| Operating income | -$662.09M | -$19.91M | -$6.12M | -$7.98M | -$14.53M | -$22.18M | -$26.28M | -$24.42M |
| Interest expense | $2.19M | $2.16M | $2.13M | $2.21M | $2.27M | $2.24M | $2.21M | $2.31M |
| Income tax | $4.64M | $2.72M | $2.35M | $2.06M | $0 | $0 | $0 | — |
| Net income | -$668.33M | -$18.55M | -$6.97M | -$8.37M | -$12.59M | -$20.34M | -$25.12M | -$23.11M |
| EBITDA | -$661.29M | -$19.11M | -$5.92M | -$7.77M | -$14.33M | -$21.98M | -$26.06M | -$24.23M |
| EPS (basic) | -14.40 | -0.43 | -0.16 | — | -0.30 | -0.48 | -0.64 | — |
| EPS (diluted) | -14.40 | -0.43 | -0.16 | — | -0.30 | -0.48 | -0.64 | — |
| Weighted avg. shares (diluted) | 46.42M | 43.39M | 42.96M | — | 42.61M | 42.36M | 39.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $136.53M | $204.59M | $102.19M | $183.64M | $115.29M | $99.21M | $178.35M | $97.38M |
| Short-term investments | $173.08M | $245.09M | $286.54M | $233.63M | $289.11M | $284.50M | $232.13M | $196.56M |
| Receivables | $100.44M | $96.03M | $100.34M | $85.06M | $72.62M | $58.33M | $62.43M | $46.76M |
| Inventory | $5.16M | $4.38M | $4.57M | $4.37M | $3.84M | $3.87M | $2.71M | $2.62M |
| Current assets | $445.42M | $561.99M | $537.23M | $522.78M | $501.70M | $474.43M | $480.77M | $356.70M |
| PP&E, net | $20.72M | $20.49M | $17.67M | $11.66M | $5.75M | $3.18M | $2.79M | $2.31M |
| Intangibles | $16.64M | $6.88M | $7.13M | $7.37M | $7.61M | $7.85M | $8.09M | $8.33M |
| Total assets | $505.50M | $611.14M | $581.13M | $562.16M | $534.56M | $494.99M | $500.75M | $376.99M |
| Current liabilities | $227.11M | $175.75M | $143.51M | $135.69M | $117.05M | $90.25M | $86.31M | $80.61M |
| Long-term debt | $72.94M | $72.76M | $72.60M | $72.44M | $72.28M | $72.13M | $71.98M | $71.84M |
| Total debt | $72.94M | $72.76M | $72.60M | $72.44M | $72.28M | $72.13M | $71.98M | $71.84M |
| Total liabilities | $401.47M | $264.41M | $232.18M | $218.73M | $199.48M | $162.38M | $158.29M | $152.46M |
| Shareholders' equity | $104.03M | $346.73M | $348.95M | $343.43M | $335.08M | $332.61M | $342.46M | $224.53M |
| Net debt | -$63.59M | -$131.83M | -$29.59M | -$111.20M | -$43.01M | -$27.08M | -$106.37M | -$25.54M |
| Shares outstanding | 49.30M | 43.27M | 43.02M | 42.55M | 42.45M | 42.21M | 42.00M | 38.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.00M | $61.22M | -$24.65M | $19.33M | $18.26M | -$29.39M | -$20.65M | -$22.18M |
| Capital expenditure | $1.21M | $4.07M | $5.82M | $6.36M | $1.91M | $1.00M | $590,000 | $72,000 |
| Free cash flow | -$7.21M | $57.15M | -$30.47M | $12.97M | $16.35M | -$30.39M | -$21.24M | -$22.25M |
| Investing cash flow | -$189.49M | $37.88M | -$58.56M | $49.27M | -$4.74M | -$51.70M | -$34.94M | -$59.57M |
| Financing cash flow | $127.81M | $3.30M | $1.20M | $2.31M | $2.56M | $1.95M | $136.56M | $2.93M |
| Depreciation & amortization | $800,000 | $800,000 | $197,000 | $202,000 | $200,000 | $200,000 | $220,000 | $192,000 |
| Stock-based compensation | $27.22M | $13.29M | $11.97M | $14.31M | $12.24M | $8.23M | $6.93M | $7.40M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.